ECSP13012603A - Nueva formulacion del cetp(1) - Google Patents

Nueva formulacion del cetp(1)

Info

Publication number
ECSP13012603A
ECSP13012603A ECSP13012603A ECSP13012603A EC SP13012603 A ECSP13012603 A EC SP13012603A EC SP13012603 A ECSP13012603 A EC SP13012603A EC SP13012603 A ECSP13012603 A EC SP13012603A
Authority
EC
Ecuador
Prior art keywords
cetp
new formulation
formulation
new
diseases
Prior art date
Application number
Other languages
English (en)
Inventor
Bernard Meyer
Michacla Krabichler
Carsten Winzenburg
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43759428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012603(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP13012603A publication Critical patent/ECSP13012603A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una formulación basada en una matriz higroscópica, a un proceso para la fabricación de la misma y a su utilización para el tratamiento de enfermedades.
ECSP13012603 2010-11-04 2013-05-03 Nueva formulacion del cetp(1) ECSP13012603A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10190045 2010-11-04

Publications (1)

Publication Number Publication Date
ECSP13012603A true ECSP13012603A (es) 2013-07-31

Family

ID=43759428

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012603 ECSP13012603A (es) 2010-11-04 2013-05-03 Nueva formulacion del cetp(1)

Country Status (25)

Country Link
US (1) US9107836B2 (es)
EP (1) EP2635263B1 (es)
JP (1) JP5676005B2 (es)
KR (1) KR101579659B1 (es)
CN (2) CN103200935A (es)
AR (1) AR083693A1 (es)
BR (1) BR112013010704B8 (es)
CA (1) CA2815280C (es)
CL (1) CL2013001164A1 (es)
CR (1) CR20130181A (es)
EA (1) EA025649B1 (es)
EC (1) ECSP13012603A (es)
ES (1) ES2553279T3 (es)
IL (1) IL225780B (es)
MA (1) MA34643B1 (es)
MX (1) MX345650B (es)
MY (1) MY164729A (es)
NZ (1) NZ609529A (es)
PE (1) PE20140018A1 (es)
PH (1) PH12013500864A1 (es)
SG (1) SG190025A1 (es)
TW (1) TWI507192B (es)
UA (1) UA110117C2 (es)
WO (1) WO2012059447A1 (es)
ZA (1) ZA201302954B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293727B2 (en) 2009-02-10 2012-10-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
BR112015024116A2 (pt) 2013-03-27 2017-10-24 Hoffmann La Roche marcadores genéticos para prever capacidade de resposta à terapia
JP5871984B2 (ja) * 2013-04-15 2016-03-01 株式会社三和化学研究所 オルメサルタンメドキソミルを含有する医薬組成物
RU2016127357A (ru) 2013-12-19 2018-01-24 Ф. Хоффманн-Ля Рош Аг Модулятор сетр для применения в лечении заболеваний глаз
JP6854752B2 (ja) 2014-07-30 2021-04-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｄｌ上昇剤又はｈｄｌ模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー
CN104434913A (zh) * 2014-12-20 2015-03-25 长沙佰顺生物科技有限公司 一种安塞曲匹药物组合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
US7208465B2 (en) * 2000-11-03 2007-04-24 The Procter & Gamble Company Methods and compositions for improved fragrancing of a surface
CA2509688A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
PL1603553T3 (pl) * 2003-03-17 2012-04-30 Japan Tobacco Inc Kompozycje farmaceutyczne inhibitorów CETP
CA2519458A1 (en) 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
MXPA06001506A (es) * 2003-08-04 2006-05-15 Pfizer Prod Inc Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa.
DE602006004558D1 (de) 2005-01-28 2009-02-12 Pfizer Prod Inc Schnell zerfallendes mikroporöses bindemittel und herstellungsverfahren dafür
US7435849B2 (en) 2005-10-31 2008-10-14 Hoffmann-La Roche Inc. Process for the production of acid chlorides
EP1935867A1 (en) 2006-12-20 2008-06-25 F. Hoffmann-La Roche Ag Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid
AU2009326326B2 (en) * 2008-12-08 2015-05-21 F. Hoffmann-La Roche Ag Combined drug administration
US20110004011A1 (en) 2009-07-01 2011-01-06 Declan Costello Novel process

Also Published As

Publication number Publication date
ZA201302954B (en) 2016-01-27
CR20130181A (es) 2013-05-29
CN103200935A (zh) 2013-07-10
EP2635263B1 (en) 2015-09-23
AU2011325235A8 (en) 2016-02-04
CL2013001164A1 (es) 2013-12-27
PH12013500864A1 (en) 2017-08-23
BR112013010704B1 (pt) 2021-06-29
CA2815280A1 (en) 2012-05-10
AR083693A1 (es) 2013-03-13
ES2553279T3 (es) 2015-12-07
NZ609529A (en) 2015-06-26
MX345650B (es) 2017-02-09
TWI507192B (zh) 2015-11-11
JP5676005B2 (ja) 2015-02-25
CN105833283A (zh) 2016-08-10
EP2635263A1 (en) 2013-09-11
SG190025A1 (en) 2013-06-28
UA110117C2 (uk) 2015-11-25
EA025649B1 (ru) 2017-01-30
WO2012059447A1 (en) 2012-05-10
BR112013010704A2 (pt) 2016-08-09
JP2013541572A (ja) 2013-11-14
EA201390622A1 (ru) 2013-10-30
AU2011325235A1 (en) 2013-05-02
KR20130083922A (ko) 2013-07-23
TW201300104A (zh) 2013-01-01
AU2011325235B2 (en) 2016-01-21
IL225780A0 (en) 2013-06-27
BR112013010704B8 (pt) 2021-11-09
MY164729A (en) 2018-01-30
IL225780B (en) 2018-10-31
CA2815280C (en) 2016-08-09
PE20140018A1 (es) 2014-01-31
MX2013004584A (es) 2013-05-17
US9107836B2 (en) 2015-08-18
MA34643B1 (fr) 2013-11-02
US20120115946A1 (en) 2012-05-10
KR101579659B1 (ko) 2015-12-22

Similar Documents

Publication Publication Date Title
UY39646A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
ECSP15001882A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
HUE045629T2 (hu) Készítmények, alkalmazások és eljárások anyagcsere rendellenességek és betegségek kezelésére
CO2018003224A2 (es) Formulaciones de aminoacidos de liberacion modificada administradas oralmente
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
GEAP201813881A (en) Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
CL2017000053A1 (es) Anticuerpos de unión a protofibrillas aß
AR087451A1 (es) Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
CR20150211A (es) Compuestos diméricos
ECSP13012603A (es) Nueva formulacion del cetp(1)
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
CL2013000310A1 (es) Compuestos derivados de tetrahidrofuranilo disustituidos y sus sales, como antagonistas del receptor b1 de bradiquinina; medicamento que contiene a dichos compuestos; su procedimiento de preparacion, util para el tratamiento agudo o profilactico de dolores agudos, osteoartritis, asma, alergias, entre otras enfermedades.
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
IN2013MU02576A (es)
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
EA201690938A1 (ru) Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания
MX353410B (es) Tinturas ácidas, proceso para su producción y su uso.
DOP2015000290A (es) Benzoxazoles sustituidos